Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma.
Balakirouchenane D, Guégan S, Csajka C, Jouinot A, Heidelberger V, Puszkiel A, Zehou O, Khoudour N, Courlet P, Kramkimel N, Lheure C, Franck N, Huillard O, Arrondeau J, Vidal M, Goldwasser F, Maubec E, Dupin N, Aractingi S, Guidi M, Blanchet B. Balakirouchenane D, et al. Among authors: blanchet b. Cancers (Basel). 2020 Apr 9;12(4):931. doi: 10.3390/cancers12040931. Cancers (Basel). 2020. PMID: 32283865 Free PMC article.
More on aprepitant for erlotinib-induced pruritus.
Mir O, Blanchet B, Goldwasser F. Mir O, et al. Among authors: blanchet b. N Engl J Med. 2011 Feb 3;364(5):487. doi: 10.1056/NEJMc1013027. N Engl J Med. 2011. PMID: 21288111 No abstract available.
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Faivre L, Gomo C, Mir O, Taieb F, Schoemann-Thomas A, Ropert S, Vidal M, Dusser D, Dauphin A, Goldwasser F, Blanchet B. Faivre L, et al. Among authors: blanchet b. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 1;879(23):2345-50. doi: 10.1016/j.jchromb.2011.06.026. Epub 2011 Jun 22. J Chromatogr B Analyt Technol Biomed Life Sci. 2011. PMID: 21737360
Drug-induced effects on erlotinib metabolism.
Mir O, Blanchet B, Goldwasser F. Mir O, et al. Among authors: blanchet b. N Engl J Med. 2011 Jul 28;365(4):379-80. doi: 10.1056/NEJMc1105083. N Engl J Med. 2011. PMID: 21793762 No abstract available.
Saturable absorption of sorafenib in patients with solid tumors: a population model.
Hornecker M, Blanchet B, Billemont B, Sassi H, Ropert S, Taieb F, Mir O, Abbas H, Harcouet L, Coriat R, Dauphin A, Goldwasser F, Tod M. Hornecker M, et al. Among authors: blanchet b. Invest New Drugs. 2012 Oct;30(5):1991-2000. doi: 10.1007/s10637-011-9760-z. Epub 2011 Oct 18. Invest New Drugs. 2012. PMID: 22006162 Clinical Trial.
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Arrondeau J, Mir O, Boudou-Rouquette P, Coriat R, Ropert S, Dumas G, Rodrigues MJ, Rousseau B, Blanchet B, Goldwasser F. Arrondeau J, et al. Among authors: blanchet b. Invest New Drugs. 2012 Oct;30(5):2046-9. doi: 10.1007/s10637-011-9764-8. Epub 2011 Oct 29. Invest New Drugs. 2012. PMID: 22038662
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Pécuchet N, Lebbe C, Mir O, Billemont B, Blanchet B, Franck N, Viguier M, Coriat R, Tod M, Avril MF, Goldwasser F. Pécuchet N, et al. Among authors: blanchet b. Br J Cancer. 2012 Jul 24;107(3):455-61. doi: 10.1038/bjc.2012.287. Epub 2012 Jul 5. Br J Cancer. 2012. PMID: 22767146 Free PMC article. Clinical Trial.
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B. Boudou-Rouquette P, et al. Among authors: blanchet b. PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912756 Free PMC article.
153 results